financetom
Business
financetom
/
Business
/
Update: Alphabet's YouTube Might Reportedly Be Added to Australian Regulator's Under-16 Social Media Ban
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Alphabet's YouTube Might Reportedly Be Added to Australian Regulator's Under-16 Social Media Ban
Jun 24, 2025 4:45 AM

07:25 AM EDT, 06/24/2025 (MT Newswires) -- (Updates with YouTube's ( GOOG ) response in the fifth, sixth, and seventh paragraphs.)

Alphabet's (GOOG, GOOGL) YouTube ( GOOG ) is being considered in the upcoming ban on social media by the Australian regulator for children under 16, multiple media outlets reported Tuesday, citing internet safety commissioner Julie Inman Grant.

The platform was reportedly initially exempt due to its educational content, but Inman Grant said new research showed nearly 40% of surveyed children encountered harmful material on the site.

YouTube's ( GOOG ) recommendation algorithms often expose users to distressing content and raised concerns over reported staff reductions in its online safety teams, the news outlets quoted Grant as saying.

The communications ministry reportedly said it would assess the recommendation but has not made a final decision.

In a blog post Tuesday, YouTube Australia said the commissioner's recommendation was "in direct contradiction to the government's decision to exempt YouTube ( GOOG ) from the ban" and cited government research that showed YouTube ( GOOG ) is appropriate for children.

"YouTube ( GOOG ) is not a social media platform; it is a video streaming platform with a library of free, high-quality content, and TV screens are increasingly the most popular place to watch," the online video sharing platform said.

"We urge the government to follow through on the public commitment it made to ensure young Australians can continue to access enriching content on YouTube ( GOOG )," it added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved